New trial at NIH (Bethesda, Maryland)
*UPDATE March 20th: RECRUITING
*Only for MSS CRC*Only for UNTREATED MSS CRC (recently diagnosed)
*Randomized (but "Arm A participants can join Arm B").
*FIRST, it will be "A LEAD IN COHORT, comprising THE FIRST 6 EVALUABLE SUBJECTS ENROLLED".
* Arm A: Ad-CEA vaccine + Avelumab (anti PD-L1) + standard of care
Arm B: standard of care
*"Standard of care" means: FOLFOX + Avastin; later, Xeloda + Avastin
Meaning, the arm A gets two immunotherapies --Avelumab, a PD-L1 antibody plus an adenoviral vector vaccine against CEA--- ADDED to standard of care. And, as said, it indicates "Arm A participants can join Arm B".
*NCI-17-C-0057 (NCI Protocol ID)
Investigator: Austin G. Duffy, M.D. Referral contact: Diana Martin, R.N. email@example.com
... 301.451.2163 301-496-9574https://clinicaltrials.gov/ct2/show/study/NCT03050814
And that should show to any oncologist how immunotherapy trials are NOT the last resource.